{"url_path":"/sec/lbrx/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1691082/0001193125-26-343479-index.html","accession_number":"0001193125-26-343479","cik":"0001691082","ticker":"LBRX","issuer_name":"LB PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1691082/0001193125-26-343479-index.html","primary_entity_key":"0001691082","primary_entity_name":"LB PHARMACEUTICALS INC"},"word_count":155,"has_tables":true,"body_markdown":"Item 2.02\n\nResults of Operations and Financial Condition.\n\nOn August 11, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished hereto as Exhibit 99.1.\n\nThe information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained in this Item 2.02 and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing."}